Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
Arthritis Research & Therapy · 18.06.2024 · 26 (1)
DOI: 10.1186/s13075-024-03353-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Research & Therapy, online erschienen am 18.06.2024. Verfasst von Javier Narváez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga, s/n, Hospitalet de …. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Rituximab, Myositis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD).
Methods
Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants.
Results
Twenty-eight patients were analyzed. Examining the entire study population, before treatment with RTX the mean decline in %pFVC and %pDLCO from the ASS-ILD diagnosis to the initiation of RTX treatment (T0) was -6.44% and -14.85%, respectively. After six months of treatment, RTX reversed the decline in pulmonary function test (PFT) parameters: ∆%pFVC +6.29% (95% CI: -10.07 to 2.51; p =0.002 compared to T0) and ∆%pDLCO +6.15% (95% CI: -10.86 to -1.43; p =0.013). Twenty-four patients completed one year of therapy and 22 two years, maintaining the response in PFT: ∆%pFVC: +9.93% (95% CI: -15.61 to -4.25; p =0.002) and ∆%pDLCO: +7.66% (95% CI: -11.67 to -3.65; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Hospital Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga, s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. fjnarvaez@bellvitgehospital.cat.
- Department of Rheumatology, Hospital Clínico, Universitario Lozano Blesa, Zaragoza, Spain.
- Department of Rheumatology. Hospital, Universitario de la Santa Creu i Sant Pau, Barcelona, Spain.
- Department of Rheumatology. Hospital, Universitario Dr Peset, Valencia, Spain.
- Interstitial Lung Disease Unit, Department of Pneumology. Hospital, Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- Department of Rheumatology, Hospital Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga, s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
ORCID-Profile: Javier Narváez, Iván Castellví, Juan José Alegre, María Molina Molina, Joan Miquel Nolla
Zitieren
APA
Narváez, J., Cañadillas, E., Castellví, I., Alegre, J. J., Vicens-Zygmunt, V., Bermudo, G., Vidal-Montal, P., Molina Molina, M., & Nolla, J. M. (2024). Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03353-2
Vancouver
Narváez J, Cañadillas E, Castellví I, Alegre JJ, Vicens-Zygmunt V, Bermudo G, et al. Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome. Arthritis Research & Therapy. 2024;26(1). doi:10.1186/s13075-024-03353-2
BibTeX
@article{Narvez2024,
author = {Narváez, Javier and Cañadillas, Elena and Castellví, Iván and Alegre, Juan José and Vicens-Zygmunt, Vanesa and Bermudo, Guadalupe and Vidal-Montal, Paola and Molina Molina, María and Nolla, Joan Miquel},
title = {Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome},
journal = {Arthritis Research & Therapy},
year = {2024},
volume = {26},
number = {1},
doi = {10.1186/s13075-024-03353-2}
}
EUVIMED